Study Design
DesignRandomized, double-blind, active-controlled and placebo-controlled
BlindingDouble-blind
Treatment Arms
Icotrokinra QD Oral once daily
Deucravacitinib 6mg QD 6mg oral once daily
Placebo Matching oral placebo
[{"id":"iga01-w16","name":"IGA 0/1 at Week 16","type":"PRIMARY","unit":"%","results":[{"value":68,"arm_id":"ico-arm","p_value":0.001,"vs_placebo":"vs deucravacitinib"},{"value":50,"arm_id":"deuc-arm"},{"value":11,"arm_id":"pbo-arm"}],"timepoint":"Week 16","description":"Head-to-head superiority of oral IL-23R antagonist vs oral TYK2 inhibitor."}]
Decisive H2H oral vs oral. Icotrokinra beat Sotyktu on every endpoint — IGA 0/1, PASI 90, PASI 100, IGA 0. This data effectively shows Sotyktu will be displaced when icotrokinra launches.